Table 2 Comparison between 78 critically ill patients with SARS-CoV-2 pneumonia developing (n = 26) or not (n = 52) eosinophilia (eosinophils count > 500mm3) during ICU stay
From: Eosinophilia in critically ill COVID-19 patients: a French monocenter retrospective study
All patients N = 78 | Patients with eosinophilia N = 26 | Patients without eosinophilia N = 52 | p | |
|---|---|---|---|---|
Patients characteristics and ICU scores | ||||
Male sex | 62 (79) | 22 (85) | 40 (77) | 0.62 |
Age, years | 62 [54–70] | 62 [55–70] | 62 [54–70] | 0.84 |
SOFA | 4 [3–7] | 4 [3–7] | 4 [3–8] | 0.44 |
SAPS II | 33 [22–44] | 34 [28–38] | 31 [19–44] | 0.72 |
Days between disease onset and ICU admission | 8 [7–12] | 10 [7–13] | 8 [7–12] | 0.28 |
Main comorbidities, n (%) | ||||
Obesity (body mass index ≥ 30 kg/m2) | 36 (46) | 9 (36) | 27 (53) | 0.25 |
Arterial hypertension | 51 (65) | 13 (50) | 38 (73) | 0.08 |
Diabetes mellitus | 33 (42) | 12 (46) | 21 (40) | 0.81 |
Ischemic cardiopathy | 8 (10) | 3 (12) | 5 (10) | 1.00 |
Cerebro-vascular diseases | 7 (9) | 4 (15) | 3 (6) | 0.21 |
Venous thrombo-embolism | 5 (6) | 2 (8) | 3 (6) | 1.00 |
Chronic respiratory diseases | 18 (23) | 6 (24) | 12 (24) | 1.00 |
Chronic renal failure | 7 (9) | 2 (8) | 5 (10) | 1.00 |
Recent cancer or hemopathy | 3 (4) | 1 (4) | 2 (4) | 1.00 |
ACE or ARB | 35 (45) | 11 (42) | 24 (47) | 0.88 |
Biological data at ICU admission | ||||
Median eosinophils count (cell/mm3) | 0 [0–10] | 5 [0–20] | 0 [0–10] | 0.43 |
Eosinophilia (> 500/mm3) | 1 (1) | 1 (4) | 0 (0) | 0.33 |
Eosinopenia (< 40/mm3) | 69 (88) | 22 (85) | 47 (90) | 0.47 |
No eosinophils | 47 (60) | 13 (50) | 34 (65) | 0.29 |
Fibrinogen (g/L) | 8 [6–9] | 7 [6–8] | 8 [7–9] | 0.37 |
D-dimers (µg/mL) | 2440 [1570–9915] | 2415 [1968–13670] | 2720 [1400–7250] | 0.36 |
Prothrombin time (%) | 85 [75–96] | 87 [80–96] | 85 [70–96] | 0.59 |
Platelets count (G/L) | 225 [164–291] | 209 [190–327] | 226 [161–272] | 0.34 |
Treatment for SARSCoV-2 pneumonia | ||||
Glucocorticoidsa | 12 (15) | 4 (15) | 8 (15) | 1.00 |
Hydroxychloroquineb | 2 (3) | 1 (4) | 1 (2) | 1.00 |
Azithromycin | 0 | – | – | – |
Remdesivir | 0 | – | – | – |
Lopinavir–ritonavir | 0 | – | – | – |
Tocilizumab | 0 | – | – | – |
Outcomes in the ICU | ||||
Invasive mechanical ventilation | 68 (87) | 25 (96) | 43 (83) | 0.15 |
Prone positioning | 48 (62) | 18 (69) | 30 (58) | 0.46 |
Vasopressor support | 49 (63) | 19 (73) | 30 (58) | 0.28 |
Acute kidney failure | 55 (71) | 19 (79) | 36 (69) | 0.53 |
Renal replacement therapy | 24 (31) | 12 (46) | 12 (23) | 0.07 |
Ventilator-associated pneumonia | 45 (58) | 19 (73) | 26 (50) | 0.09 |
Thrombotic event during ICU stay | 33 (42) | 12 (48) | 21 (40) | 0.70 |
Length of ICU stay, days | 16 [8–30] | 31 [23–52] | 12 [6–21] | < 0.001 |
ICU mortality | 38 (49) | 9 (35) | 29 (56) | 0.13 |
Days between ICU admission and death | 13 (8–21) | 23 (18–47) | 12 (8–16) | < 0.001 |